Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Change in Receivables (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Change in Receivables for 7 consecutive years, with -$169000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 77.89% year-over-year to -$169000.0, compared with a TTM value of -$863000.0 through Dec 2025, down 114.68%, and an annual FY2025 reading of -$863000.0, down 114.68% over the prior year.
  • Change in Receivables was -$169000.0 for Q4 2025 at aTYR PHARMA, down from $544000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $12.0 million in Q4 2022 and bottomed at -$9.9 million in Q1 2023.
  • Average Change in Receivables over 5 years is $0.0, with a median of -$56000.0 recorded in 2024.
  • The sharpest move saw Change in Receivables soared 3819.28% in 2022, then tumbled 109711.11% in 2023.
  • Year by year, Change in Receivables stood at $306000.0 in 2021, then skyrocketed by 3819.28% to $12.0 million in 2022, then plummeted by 96.18% to $458000.0 in 2023, then tumbled by 120.74% to -$95000.0 in 2024, then tumbled by 77.89% to -$169000.0 in 2025.
  • Business Quant data shows Change in Receivables for ATYR at -$169000.0 in Q4 2025, $544000.0 in Q3 2025, and -$490000.0 in Q2 2025.